美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ophthotech Corporation

1.39

0.0000

成交量：- -

成交額：- -

市值：5,757.60萬

市盈率：0.82

高：1.39

開：1.39

低：1.39

收：1.39

52周最高：4.50

52周最低：1.02

股本：4,142.15萬

流通股本：2,660.83萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):1.70

每股收益(LYR):1.70

淨資產收益率：--

總資產收益率：--

市淨率：0.46

市盈率(LYR):0.82

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Ophthotech Corporation

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.ophthotech.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Ophthotech Corporation成立於2007年1月5日，在美國特拉華州。公司是一家生物製藥公司，專門從事新型療法的發展，治療眼睛的背部疾病，重點開發治療年齡相關性黃斑變性，或AMD。公司的最先進產品的候選是Fovista，這是在第3階段的臨床開發組合使用與代表保健為濕性AMD的治療的目前標準的抗VEGF藥物。公司已完成了第一階段1和一個2b期Fovista的組合給予的抗VEGF藥物Lucentis的臨床試驗。公司也正在開發其候選產品Zimura，對於患者的地理萎縮，乾性AMD的一種形式的治療，結合抗VEGF療法用於治療息肉狀脈絡膜血管病變，濕性AMD的特定類型，患者誰不與抗-VEGF單一療法充分應對處理或為其抗-VEGF單一療法失敗，並且，潛在地，在用抗VEGF治療和Fovista對於抗VEGF抗性濕性AMD的患者的治療中誰被認為具有補體結合介導的炎症。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OPHT/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OPHT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPHT\",,,,,undefined,":{"symbol":"OPHT","market":"US","secType":"STK","nameCN":"Ophthotech Corporation","latestPrice":1.39,"timestamp":1567195200000,"preClose":1.39,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":26608262,"shares":41421548,"eps":1.7,"marketStatus":"盤後交易","change":0,"latestTime":"02-23 16:43:39 EST","open":1.39,"high":1.39,"low":1.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.7,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1771894800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPHT\",,,,,undefined,":{"symbol":"OPHT","floatShares":26608262,"roa":"--","roe":"--","lyrEps":1.702247,"shares":41421548,"dividePrice":0,"high":1.39,"amplitude":0,"preClose":1.39,"low":1.39,"week52Low":1.02,"pbRate":"0.46","week52High":4.5,"institutionHeld":0,"latestPrice":1.39,"eps":1.7,"divideRate":0,"volume":0,"delay":0,"ttmEps":1.7,"open":1.39,"prevYearClose":1.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPHT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-26","symbol":"OPHT","fiscalQuarterEnding":"2018/12","expectedEps":-0.36,"name":null,"time":"盤前","type":"earning","dateTimestamp":1551157200000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2018-10-31","symbol":"OPHT","fiscalQuarterEnding":"2018/09","expectedEps":-0.43,"name":null,"time":"盤前","type":"earning","dateTimestamp":1540958400000,"reportTimeType":"pre","actualEps":-0.41},{"market":"US","date":"2018-08-01","symbol":"OPHT","fiscalQuarterEnding":"2018/06","expectedEps":-0.4,"name":null,"time":"盤前","type":"earning","dateTimestamp":1533096000000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2018-05-09","symbol":"OPHT","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1525838400000,"reportTimeType":"pre","actualEps":-0.36},{"market":"US","date":"2018-02-27","symbol":"OPHT","fiscalQuarterEnding":"2017/12","expectedEps":-0.58,"name":null,"time":"盤前","type":"earning","dateTimestamp":1519707600000,"reportTimeType":"pre","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPHT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OPHT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ophthotech.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Ophthotech Corporation成立於2007年1月5日，在美國特拉華州。 公司是一家生物製藥公司，專門從事新型療法的發展，治療眼睛的背部疾病，重點開發治療年齡相關性黃斑變性，或AMD。 公司的最先進產品的候選是Fovista，這是在第3階段的臨床開發組合使用與代表保健為濕性AMD的治療的目前標準的抗VEGF藥物。公司已完成了第一階段1和一個2b期Fovista的組合給予的抗VEGF藥物Lucentis的臨床試驗。公司也正在開發其候選產品Zimura，對於患者的地理萎縮，乾性AMD的一種形式的治療，結合抗VEGF療法用於治療息肉狀脈絡膜血管病變，濕性AMD的特定類型，患者誰不與抗-VEGF單一療法充分應對處理或為其抗-VEGF單一療法失敗，並且，潛在地，在用抗VEGF治療和Fovista對於抗VEGF抗性濕性AMD的患者的治療中誰被認為具有補體結合介導的炎症。","exchange":"NASDAQ","name":"Ophthotech Corporation","nameEN":"Ophthotech"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OPHT\",market:\"US\",,,undefined,":null}}